日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Combination of GLP-1 receptor agonist and Akkermansia muciniphila Akk11 reduces adiposity and ameliorates MASLD in T2D mice.

GLP-1 受体激动剂与 Akkermansia muciniphila Akk11 的组合可减少 T2D 小鼠的脂肪堆积并改善 MASLD。

Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

一项随机、双盲、安慰剂对照的2b期临床试验,旨在评估GLP-1受体激动剂波方鲁肽在中国超重或肥胖成年人中的疗效和安全性。

Ji, Linong; Gao, Leili; Tian, Junhang; Dong, Ruihua; Zhang, Zhongtao; Shu, Hongyan; Zhao, Jing; Zhao, Liyuan; He, Anshun; Xie, Tian; Li, Yue; Chen, Wei

GLP-1 receptor agonists for obesity: eligibility across 99 countries

GLP-1受体激动剂治疗肥胖症:99个国家的适用性

Yoo, Sang Gune K; Teufel, Felix; Theilmann, Michaela; Si, Yajuan; Toure, Elhadji A; Aryal, Krishna; Bärnighausen, Till; Bait, Abdul; Barreto, Marta; Bovet, Pascal; Brant, Luisa C C; Cuschieri, Sarah; Damasceno, Albertino; Farzadfar, Farshad; Fawwad, Asher; Geldsetzer, Pascal; Hambleton, Ian R; Houehanou, Corine; Howitt, Christina; J Rgensen, Jutta; González-Rivas, Juan P; Labadarios, Demetre; Marcus, Maja; Martins, Joao; Mwalim, Omar; Nieto-Martínez, Ramfis; Odili, Augustine N; Orazumbekova, Binur; Perman, Gastón; Quesnel-Crooks, Sarah; Moghaddam, Sahar Saeedi; Sewpal, Ronel; Sousa-Uva, Mafalda; Sulola, Mubarak A; Venkataraman, Kavita; Vollmer, Sebastian; Xueling, Sim; Atun, Rifat; Banegas, José R; Franco, Juan V A; Arnott, Clare; Chandiwana, Nomathemba; Huffman, Mark D; Davies, Justine; Ali, Mohammed K; Flood, David; Manne-Goehler, Jennifer

Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants

DPP-4抑制剂、GLP-1受体激动剂和SGLT2抑制剂的药物特异性、组织病理学分层血液系统恶性肿瘤风险:一项纳入270,471名参与者的网络荟萃分析

Lin, Pao-Yen; Zeng, Bing-Syuan; Chen, Jiann-Jy; Zeng, Bing-Yan; Suen, Mein-Woei; Hung, Chao-Ming; Hsu, Chih-Wei; Stubbs, Brendon; Chen, Yen-Wen; Chen, Tien-Yu; Lei, Wei-Te; Hsu, Shih-Pin; Shiue, Yow-Ling; Su, Kuan-Pin; Li, Cheng-Ta; Wang, Hung-Yu; Tseng, Ping-Tao; Liang, Chih-Sung

GLP-1RA Use and the Risk of Heart Failure in Patients With Diabetes: Association or Causation?

GLP-1RA的使用与糖尿病患者发生心力衰竭的风险:是相关性还是因果关系?

Inoue, Kosuke; Kazi, Dhruv S

SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes

SGLT2抑制剂与GLP-1受体激动剂对2型糖尿病患者肾脏结局的影响

Jensen, Simon K; Heide-Jørgensen, Uffe; Andersen, Ina T; Bonnesen, Kasper; Fu, Edouard L; Thomsen, Reimar W; Christiansen, Christian F

Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial

上消化道内镜检查前停用与继续使用GLP-1/GIP激动剂的比较:OCULUS随机临床试验

Ahmad, Akram I; Garg, Samita; Jacobs, Jeffrey; Ansari, Zaid; Al-Din, Tasneem Jamal; Almomani, Ashraf; Valencia, Sara; Vargo, John; Chatterjee, Arjun; Siddiki, Hassan; Hong, Liang; Nicolas, Michael A; Miller, Alaina; Shah, Tilak

GLP-1 Receptor Agonist Prescriptions for Adolescents With Obesity and Associated Disparities

GLP-1受体激动剂处方在肥胖青少年中的应用及相关差异

Kim, Chungsoo; Sharifi, Mona; Ross, Joseph S; Chen, Yong; Xu, Hua; Krumholz, Harlan M; Lu, Yuan

Early cancer risk reduction after GLP-1RA use: Signal or bias?: Letter to the editor on "Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study"

GLP-1RA 使用后早期癌症风险降低:信号还是偏倚?:致编辑的信,主题为“胰高血糖素样肽-1受体激动剂可降低2型糖尿病合并代谢功能障碍相关脂肪肝病成人患者的肝脏和非肝脏并发症:一项目标试验模拟研究”

Jean, Shio-Shin; Lai, Chih-Cheng

GLP-1RA may open a new era for MASLD treatment: Editorial on "Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study"

GLP-1RA 或将开启 MASLD 治疗的新纪元:社论《胰高血糖素样肽-1 受体激动剂可减少 2 型糖尿病合并代谢功能障碍相关脂肪肝成人患者的肝脏和非肝脏并发症:一项目标试验模拟研究》

Feng, Ye; Xu, Chengfu